Please ensure Javascript is enabled for purposes of website accessibility

Sorrento Reports It Has a Second Potential Antidote for COVID-19

By Jim Crumly – Updated Jun 24, 2020 at 2:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug blocked the SARS-CoV-2 virus from replicating in a preclinical experiment.

On Friday, Sorrento Therapeutics (SRNE -2.42%) announced positive results from preclinical testing of STI-4398, a protein to neutralize the SARS-CoV-2 virus. The company said that the drug candidate it has nicknamed "Covidtrap" completely inhibited the ability of the coronavirus to infect cells that have the same ACE2 receptors that are present on the respiratory epithelial cells that it targets in humans.

Covidtrap is a proprietary ACE2-Fc protein designed to bind to the spike protein of SARS-CoV-2 and block it from infecting respiratory cells. Without the ability to penetrate target cells, the virus wouldn't be able to replicate and spread itself.

The company has discussed the drug with the Food and Drug Administration and has received guidance for advancing it both as a treatment for patients infected with the virus and as a prophylactic measure for preventing COVID-19. The next step will be animal studies, but the company is already making plans for clinical studies in humans.

Drop falling from pipette into a test tube.

Image source: Getty Images.

In the experiment, STI-4398 neutralized the virus and prevented it from infecting cell cultures derived from African green monkeys in a laboratory setting, but that's a long way from determining whether it can safely and effectively fight the disease in people, and the company doesn't have a timeline for that, yet.

Last month, Sorrento announced results from an in vitro experiment for STI-1499, an antibody that it said demonstrated "100% inhibition" of SARS-CoV-2, and the stock almost quadrupled in two days. Since then, shares have drifted downward as investors seemed to consider the risks ahead, despite the encouraging results in petri dishes. Friday's news that the company could have a second drug candidate that could be equally effective in fighting COVID-19 got a more muted reception from Wall Street -- while shares were up by as much as 18% in intraday trading, they closed only 6.7% higher.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics Stock Quote
Sorrento Therapeutics
SRNE
$1.61 (-2.42%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.